Drugs / ALN-6222
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07624071 | Jun 2026 → Dec 2027 expected | obesity disorder | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-6222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07624071 ↗ |
| Route | Subcutaneous | “ALN-6222 will be administered subcutaneously (SC).” NCT07624071 ↗ |